Whole exome sequencing identifies clinically relevant mutational signatures in resected hepatocellular carcinoma
Ontology highlight
ABSTRACT: We conducted a multicentre pilot study on patients with localized HCC following complete radiological response to surgical resection. Patients received 250 mg oral gefitinib once daily as adjuvant therapy, up to a maximum of 6 months. The clinical endpoints included recurrence-free survival (RFS) and overall survival (OS), and correlative genetic analyses were conducted from whole exome sequencing data (n=33). All statistical analyses were carried out on an intention-to-treat basis. The study is registered with ClinicalTrials.gov (NCT00282100).
PROVIDER: EGAS00001004371 | EGA |
REPOSITORIES: EGA
ACCESS DATA